Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

10-21	Allergan Aesthetics presents its latest scientific advances
09-29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI

Market Cap	63.66B 57.05B 52.49B 47.55B 88.94B 6,044B 90.56B 625B 252B 3,170B 239B 234B 10,036B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.55B 66.76B 60.47B 113B 7,687B 115B 795B 321B 4,032B 304B 297B 12,764B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

10-21	Allergan Aesthetics presents its latest scientific advances
09-29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI
09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

10-21	Allergan Aesthetics présente ses dernières avancées scientifiques
21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07
Andres Rodrigo BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.91%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+84.17%	658B
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+108.88%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+55.81%	+72.50%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.59%	369B
NOVARTIS AG	+1.12%	+4.52%	+34.76%	+58.24%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.95%	+36.20%	290B
AMGEN INC.	+1.15%	+6.09%	+56.15%	+82.25%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+117.32%	212B
Average	+2.08%	+5.90%	+46.58%	+84.56%	473.55B
Weighted average by Cap.	+2.01%	+6.60%	+50.51%	+100.44%

	2018	2019
Net sales	15.79B 14.15B 13.02B 11.79B 22.06B 1,499B 22.46B 155B 62.5B 786B 59.25B 57.98B 2,489B	16.09B 14.42B 13.27B 12.02B 22.48B 1,527B 22.89B 158B 63.69B 801B 60.38B 59.09B 2,536B
Net income	-5.1B -4.57B -4.2B -3.81B -7.12B -484B -7.25B -50.04B -20.17B -254B -19.13B -18.72B -803B	-5.27B -4.72B -4.35B -3.94B -7.36B -500B -7.5B -51.75B -20.87B -263B -19.78B -19.36B -831B
Net Debt	21.89B 19.62B 18.05B 16.35B 30.58B 2,078B 31.14B 215B 86.66B 1,090B 82.15B 80.39B 3,451B	17.3B 15.51B 14.27B 12.93B 24.18B 1,643B 24.62B 170B 68.5B 862B 64.94B 63.55B 2,728B

End-of-day quote NYSE
- ^USD	-